<!DOCTYPE html
  PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:n1="urn:hl7-org:v3">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=ISO-8859-1">
   
      <title>Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic</title><style type="text/css">
body {
	color: rgb(26, 26, 26);
	background-color: rgb(255,255,255);
	font-family: Verdana, Tahoma, sans-serif;
	font-size: 11px;
}

a {
	color: rgb(0, 0, 255);
	background-color: rgb(255,255,255);
}

h1 {
	font-size: 12pt;
	font-weight: bold;
}

h2 {
	font-size: 11pt;
	font-weight: bold;
}

h3 {
	font-size: 10pt;
	font-weight: bold;
}

h4 {
	font-size: 8pt;
	font-weight: bold;
}

div {
	width: 80%;
}

table {
	line-height: 10pt;
	width: 80%;
}

tr {
	background-color: rgb(224,224,224);
}

td {
	padding: 0.1cm 0.2cm;
	vertical-align: top;
}

.h1center {
	font-size: 12pt;
	font-weight: bold;
	text-align: center;
	width: 80%;
}

.header_table{
	border: 1pt inset rgb(0,0,0);
}

.narr_table {
	width: 100%;
}

.narr_tr {
	background-color: rgb(225,225,225);
}
pre {
 overflow: auto; /* Use horizontal scroller if needed; for Firefox 2, not needed in Firefox 3 */
 white-space: pre-wrap; /* css-3 */
 white-space: -moz-pre-wrap !important; /* Mozilla, since 1999 */
 white-space: -pre-wrap; /* Opera 4-6 */
 white-space: -o-pre-wrap; /* Opera 7 */
 word-wrap: break-word; /* Internet Explorer 5.5+ */
 font-family: Verdana, Tahoma, sans-serif;
 font-size: 11px;
 text-align:left;
 margin: 0px 0px 0px 0px;
 padding:0px 0px 0px 0px;
}
.narr_th {
	background-color: rgb(201,201,201);
}

.td_label{
	font-weight: bold;
	color: white;
}
	</style></head>
   <body>
      <table class="header_table">
         <tbody>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">eMeasure Title</span></td>
               <td width="80%" colspan="3">Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic</td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">eMeasure Identifier<br>(Measure Authoring Tool)</span></td>
               <td width="30%">164</td>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">eMeasure Version number</span></td>
               <td width="30%">1</td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">NQF Number</span></td>
               <td width="30%">0068</td>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">GUID</span></td>
               <td> 0713ea8f-0e5b-4099-8c7c-dd677280398f</td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Measurement Period</span></td>
               <td width="80%" colspan="3">January 1, 20xx  through December 31, 20xx </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Measure Steward</span></td>
               <td width="80%" colspan="3">National Committee for Quality Assurance</td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Measure Developer</span></td>
               <td width="80%" colspan="3">National Committee for Quality Assurance</td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Endorsed By</span></td>
               <td width="80%" colspan="3">National Quality Forum</td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Description</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had documentation of use of aspirin or another antithrombotic during the measurement period.</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Copyright</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA). 

The Measures are copyrighted but can be reproduced and distributed, without modification, for noncommercial purposes (e.g., use by healthcare providers in connection with their practices). Commercial use is defined as the sale, licensing, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial use of the Measures requires a license agreement between the user and NCQA. NCQA is not responsible for any use of the Measures. 

Copyright 2012 National Committee for Quality Assurance. All Rights Reserved. 

Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any CPT or other codes contained in the specifications.

CPT(R) contained in the Measure specifications is copyright 2004-2011 American Medical Association. LOINC(R) copyright 2004-2011 Regenstrief Institute, Inc. 
This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2011 International Health Terminology Standards Development Organisation. ICD-10 copyright 2011 World Health Organization. All Rights Reserved.

Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM].</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Disclaimer</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>These performance Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED &#8220;AS IS&#8221; WITHOUT WARRANTY OF ANY KIND.</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Measure Scoring</span></td>
               <td width="80%" colspan="3">Proportion</td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Measure Type</span></td>
               <td width="80%" colspan="3">Process</td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Stratification</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>None</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Risk Adjustment</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>None</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Rate Aggregation</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>None</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Rationale</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Coronary heart disease (CHD) is a major cause of death in the United States &#8211; in 2004, it was an underlying or contributing cause of death for 451,300 people (1 of every 5 deaths). Acute myocardial infarction (AMI) was as an underlying or contributing cause of death for 156,000 people (American Heart Association 2008). In addition, nearly 16 million people (or 7.3 percent of the American population) had CHD in 2005 (American Heart Association 2008). The cost of cardiovascular diseases and stroke in the United States for 2008 was estimated at $448.5 billion (American Heart Association 2008). This figure includes health expenditures (direct costs such as the cost of physicians and healthcare practitioners, hospital and nursing home services, medications, home health care and other medical durables) and lost productivity resulting from morbidity and mortality (indirect costs). AMI accounts for 18 percent of hospital discharges and 28 percent of deaths due to heart disease (National Heart, Lung, and Blood Institute  2000). Research has shown that costs associated with cardiovascular disease for hospitals are easily $156 billion (American Heart Association 2008).


Aspirin treatments reduce MI in men (127 events per 100,000 person-years) and women (17 events per 100,000 person-years) (Grieving et al. 2008). While studies have shown warfarin to be more effective, aspirin is a safer, more convenient, and less expensive form of therapy (Patrono et al. 2004). Aspirin therapy has been shown to directly reduce the odds of cardiovascular events among men by 14 percent and among women by 12 percent  (Berger et al. 2006). Aspirin use has been shown to reduce the number of strokes by 20 percent, MI by 30 percent, and other vascular events by 30 percent (Weisman and Graham 2002).</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Clinical Recommendation Statement</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>U.S. Preventive Services Task Force  (2009): 
The USPSTF strongly recommends that clinicians discuss aspirin chemoprevention with adults who are at increased risk (5-year risk of greater than or equal to 3 percent) for coronary heart disease (CHD). Discussions with patients should address both the potential benefits and harms of aspirin therapy. ('A' recommendation) The USPSTF recommends the use of aspirin for men age 45 to 79 years when the potential benefit due to a reduction in myocardial infarctions outweighs the potential harm due to an increase in gastrointestinal hemorrhage ('A' recommendation). The USPSTF recommends the use of aspirin for women age 55 to 79 years when the potential benefit of a reduction in ischemic stroke outweighs the potential harm of an increase in gastrointestinal hemorrhage. ('A' recommendation)

American Diabetes Association (2008): 
Use aspirin therapy (75-162 mg/day) as a secondary prevention strategy in those with diabetes with a history of CVD. (Level A). Use aspirin therapy (75-162 mg/day) as a primary prevention strategy in those with type 1 or 2 diabetes at increased cardiovascular risk, including those who are 40 years of age or who have additional risk factors (family history of CVD, hypertension, smoking, dyslipidemia, or albuminuria). (Level of Evidence: Level A)


American Heart Association/American Stroke Association  (2006): The use of aspirin is recommended for cardiovascular (including but not specific to stroke) prophylaxis among persons whose risk is sufficiently high for the benefits to outweigh the risks associated with treatment (a 10-year risk of cardiovascular events of 6 to 10 percent). (Class I: Level A)

American College of Clinical Pharmacy (2004): 
For long-term treatment after PCI, the guideline developers recommend aspirin, 75 to 162 mg/day. (Grade 1A) For long-term treatment after PCI in patients who receive antithrombotic agents such as clopidogrel or warfarin, the guideline developers recommend lower-dose aspirin, 75 to 100 mg/day. (Grade 1C+) For patients with ischemic stroke who are not receiving thrombolysis, the guideline developers recommend early aspirin therapy, 160 to 325 mg/day. (Grade 1A)</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Improvement Notation</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Higher score indicates better quality</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Reference</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>American Diabetes Association. 2008. &#8220;Standards of Medical Care in Diabetes - 2008.&#8221; Diabetes Care 31:S12-S54.</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Reference</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>U.S. Preventive Services Task Force. 2009. &#8220;Aspirin for the Prevention of Cardiovascular Disease.&#8221; (December) .  http://www.ahrq.gov/clinic/uspstf/uspsasmi.htm</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Reference</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>National Institutes of Health, National Heart, Lung, and Blood Institute. 2000. Morbidity and Mortality: 2000 Chart Book on Cardiovascular, Lung, and Blood Diseases. http://www.nhlbi.nih.gov/resources/docs/cht-book.htm</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Reference</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Grieving, J.P., E. Buskens, H. Koffijberg, A. Algra. 2008. &#8220;Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.&#8221; Circulation 117:2875-2883.</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Reference</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Patrono, C., B. Coller, G.A. FitzGerald, J. Hirsh, G. Roth. 2004. &#8220;Platelet-Active Drugs: The relationships among dose, effectiveness, and side effects: the seventh ACCP Conference on antithrombotic and thrombolytic therapy.&#8221; Chest 126:234-264.</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Reference</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Berger, J.S., M.C. Roncaglioni, F. Avanzini, I. Pangrazzi, G. Tognoni, D.L. Brown. 2006. &#8220;Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.&#8221; JAMA 296(4):306-314.</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Reference</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Weisman, S.M., and D.Y. Graham. 2002. &#8220;Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events.&#8221; Arch Intern Med 162(19):2197-2202.</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Reference</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>American Heart Association. 2008. &#8220;Heart Disease and Stroke Statistics &#8212; 2008 Update.&#8221; http://www.americanheart.org/downloadable/heart/1200082005246HS_Stats%202008.final.pdf</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Definition</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>None</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Guidance</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Only patients who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) should be included in the measure.</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Transmission Format</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>TBD</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Initial Patient Population</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Patients 18 years of age and older with a visit during the measurement period, and an active diagnosis of ischemic vascular disease (IVD) or who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Denominator</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Equals Initial Patient Population</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Denominator Exclusions</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Not Applicable</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Numerator</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Patients who have documentation of use of aspirin or another antithrombotic during the measurement period</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Numerator Exclusions</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Not Applicable</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Denominator Exceptions</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>None</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Measure Population</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Not Applicable</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Measure Observations</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Not Applicable</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Supplemental Data Elements</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>For every patient evaluated by this measure also identify payer, race, ethnicity and sex</pre></div>
               </td>
            </tr>
         </tbody>
      </table>
      <h2><a name="toc">Table of Contents</a></h2>
      <ul>
         <li><a href="#d2353590e541">Population criteria</a></li>
         <li><a href="#d2353590e1393">Data criteria (QDM Data Elements)</a></li>
         <li><a href="#d2353590e1891">Reporting Stratification</a></li>
         <li><a href="#d2353590e1912">Supplemental Data Elements</a></li>
      </ul>
      <hr align="left" color="teal" size="2" width="80%">
      <h3><a name="d2353590e541" href="#toc">Population criteria</a></h3>
      <div>
         
         <ul>
            <li>
               <b>Initial Patient Population =</b>
               
               <ul>
                  <li>AND: "Patient Characteristic Birthdate: birth date"  &gt;= 18 year(s) starts before start of "Measurement Period"</li>
                  <li>AND: 
                     <ul>
                        <li>OR: 
                           <ul>
                              <li>AND NOT: "Occurrence A of Diagnosis, Active: Ischemic Vascular Disease" ends before start of "Measurement Period"</li>
                              <li>AND: "Occurrence A of Diagnosis, Active: Ischemic Vascular Disease" starts before or during "Measurement Period"</li>
                           </ul>
                           
                        </li>
                        <li>OR: 
                           <ul>
                              <li>AND NOT: "Occurrence A of Diagnosis, Active: Acute Myocardial Infarction" ends before start of "Measurement Period"</li>
                              <li>AND: "Occurrence A of Diagnosis, Active: Acute Myocardial Infarction"  &lt;= 12 month(s) starts before start of "Measurement
                                 Period"
                              </li>
                           </ul>
                           
                        </li>
                        <li>OR: 
                           <ul>
                              <li>OR: "Procedure, Performed: Percutaneous Coronary Interventions"</li>
                              <li>OR: "Procedure, Performed: Coronary Artery Bypass Graft"</li>
                              <li>  &lt;= 12 month(s) ends before start of "Measurement Period"</li>
                           </ul>
                           
                        </li>
                     </ul>
                     
                  </li>
                  <li>AND: 
                     <ul>
                        <li>OR: "Encounter, Performed: Office Visit"</li>
                        <li>OR: "Encounter, Performed: Face-to-Face Interaction"</li>
                        <li>OR: "Encounter, Performed: Preventive Care Services - Established Office Visit, 18 and Up"</li>
                        <li>OR: "Encounter, Performed: Preventive Care Services-Initial Office Visit, 18 and Up"</li>
                        <li>OR: "Encounter, Performed: Home Healthcare Services"</li>
                        <li>OR: "Encounter, Performed: Annual Wellness Visit"</li>
                        <li> during "Measurement Period"</li>
                     </ul>
                     
                  </li>
               </ul>
               
            </li>
            <li>
               <b>Denominator =</b>
               
               <ul>
                  <li>AND: "Initial Patient Population"</li>
               </ul>
               
            </li>
            <li>
               <b>Denominator Exclusions =</b>
               
               <ul>
                  <li>None</li>
               </ul>
               
            </li>
            <li>
               <b>Numerator =</b>
               
               <ul>
                  <li>AND NOT: "Occurrence A of Medication, Active: Aspirin and Other Anti-thrombotics" ends before start of "Measurement Period"</li>
                  <li>AND: "Occurrence A of Medication, Active: Aspirin and Other Anti-thrombotics" starts before or during "Measurement Period"</li>
               </ul>
               
            </li>
            <li>
               <b>Denominator Exceptions =</b>
               
               <ul>
                  <li>None</li>
               </ul>
               
            </li>
         </ul>
         
      </div>
      <h3><a name="d2353590e1393" href="#toc">Data criteria (QDM Data Elements)</a></h3>
      <div>
         
         <ul>
            <li>
               "Diagnosis, Active: Acute Myocardial Infarction" using "Acute Myocardial Infarction Grouping Value Set (2.16.840.1.113883.3.464.1003.104.12.1001)"
            </li>
            <li>
               "Diagnosis, Active: Ischemic Vascular Disease" using "Ischemic Vascular Disease Grouping Value Set (2.16.840.1.113883.3.464.1003.104.12.1003)"
            </li>
            <li>
               "Encounter, Performed: Annual Wellness Visit" using "Annual Wellness Visit Grouping Value Set (2.16.840.1.113883.3.526.3.1240)"
            </li>
            <li>
               "Encounter, Performed: Face-to-Face Interaction" using "Face-to-Face Interaction Grouping Value Set (2.16.840.1.113883.3.464.1003.101.12.1048)"
            </li>
            <li>
               "Encounter, Performed: Home Healthcare Services" using "Home Healthcare Services Grouping Value Set (2.16.840.1.113883.3.464.1003.101.12.1016)"
            </li>
            <li>
               "Encounter, Performed: Office Visit" using "Office Visit Grouping Value Set (2.16.840.1.113883.3.464.1003.101.12.1001)"
            </li>
            <li>
               "Encounter, Performed: Preventive Care Services - Established Office Visit, 18 and Up" using "Preventive Care Services - Established Office Visit, 18 and Up Grouping Value Set (2.16.840.1.113883.3.464.1003.101.12.1025)"
            </li>
            <li>
               "Encounter, Performed: Preventive Care Services-Initial Office Visit, 18 and Up" using "Preventive Care Services-Initial Office Visit, 18 and Up Grouping Value Set (2.16.840.1.113883.3.464.1003.101.12.1023)"
            </li>
            <li>
               "Medication, Active: Aspirin and Other Anti-thrombotics" using "Aspirin and Other Anti-thrombotics Grouping Value Set (2.16.840.1.113883.3.464.1003.196.12.1211)"
            </li>
            <li>
               "Patient Characteristic Birthdate: birth date" using "birth date LOINC Value Set (2.16.840.1.113883.3.560.100.4)"
            </li>
            <li>
               "Procedure, Performed: Coronary Artery Bypass Graft" using "Coronary Artery Bypass Graft Grouping Value Set (2.16.840.1.113883.3.464.1003.104.12.1002)"
            </li>
            <li>
               "Procedure, Performed: Percutaneous Coronary Interventions" using "Percutaneous Coronary Interventions Grouping Value Set (2.16.840.1.113883.3.464.1003.104.12.1010)"
            </li>
         </ul>
         
      </div>
      <h3><a name="d2353590e1891" href="#toc">Reporting Stratification</a></h3>
      <div>
         
         <ul>
            <li>None</li>
         </ul>
         
      </div>
      <h3><a name="d2353590e1912" href="#toc">Supplemental Data Elements</a></h3>
      <div>
         
         <ul>
            <li>
               "Patient Characteristic Ethnicity: Ethnicity" using "Ethnicity CDC Value Set (2.16.840.1.114222.4.11.837)"
            </li>
            <li>
               "Patient Characteristic Payer: Payer" using "Payer Source of Payment Typology Value Set (2.16.840.1.114222.4.11.3591)"
            </li>
            <li>
               "Patient Characteristic Race: Race" using "Race CDC Value Set (2.16.840.1.114222.4.11.836)"
            </li>
            <li>
               "Patient Characteristic Sex: ONC Administrative Sex" using "ONC Administrative Sex Administrative Sex Value Set (2.16.840.1.113762.1.4.1)"
            </li>
         </ul>
         
      </div><br><hr align="left" color="teal" size="2" width="80%"><br><table class="header_table">
         <tbody>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Measure Set</span></td>
               <td colspan="3" width="80%">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto;word-wrap:break-word">None</div>
               </td>
            </tr>
         </tbody>
      </table>
   </body>
</html>